Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants
Smith, Bryan D., Kaufman, Michael D., Lu, Wei-Ping, Gupta, Anu, Leary, Cynthia B., Wise, Scott C., Rutkoski, Thomas J., Ahn, Yu Mi, Al-Ani, Gada, Bulfer, Stacie L., Caldwell, Timothy M., Chun, Lawrence, Ensinger, Carol L., Hood, Molly M., McKinley, Arin, Patt, William C., Ruiz-Soto, Rodrigo, Su, Ying, Telikepalli, Hanumaiah, Town, Ajia, Turner, Benjamin A., Vogeti, Lakshminarayana, Vogeti, Subha, Yates, Karen, Janku, Filip, Abdul Razak, Albiruni Ryan, Rosen, Oliver, Heinrich, Michael C., Flynn, Daniel L.
Published in Cancer cell (13.05.2019)
Published in Cancer cell (13.05.2019)
Get full text
Journal Article
Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
Peng, Sheng-Bin, Henry, James R., Kaufman, Michael D., Lu, Wei-Ping, Smith, Bryan D., Vogeti, Subha, Rutkoski, Thomas J., Wise, Scott, Chun, Lawrence, Zhang, Youyan, Van Horn, Robert D., Yin, Tinggui, Zhang, Xiaoyi, Yadav, Vipin, Chen, Shih-Hsun, Gong, Xueqian, Ma, Xiwen, Webster, Yue, Buchanan, Sean, Mochalkin, Igor, Huber, Lysiane, Kays, Lisa, Donoho, Gregory P., Walgren, Jennie, McCann, Denis, Patel, Phenil, Conti, Ilaria, Plowman, Gregory D., Starling, James J., Flynn, Daniel L.
Published in Cancer cell (14.09.2015)
Published in Cancer cell (14.09.2015)
Get full text
Journal Article
Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages
Smith, Bryan D, Kaufman, Michael D, Wise, Scott C, Ahn, Yu Mi, Caldwell, Timothy M, Leary, Cynthia B, Lu, Wei-Ping, Tan, Gege, Vogeti, Lakshminarayana, Vogeti, Subha, Wilky, Breelyn A, Davis, Lara E, Sharma, Maitreyi, Ruiz-Soto, Rodrigo, Flynn, Daniel L
Published in Molecular cancer therapeutics (01.11.2021)
Published in Molecular cancer therapeutics (01.11.2021)
Get full text
Journal Article
Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT)
Caldwell, Timothy M., Ahn, Yu Mi, Bulfer, Stacie L., Leary, Cynthia B., Hood, Molly M., Lu, Wei-Ping, Vogeti, Lakshminarayana, Vogeti, Subha, Kaufman, Michael D., Wise, Scott C., Le Bourdonnec, Bertrand, Smith, Bryan D., Flynn, Daniel L.
Published in Bioorganic & medicinal chemistry letters (15.10.2022)
Published in Bioorganic & medicinal chemistry letters (15.10.2022)
Get full text
Journal Article
Chemoproteomic Evaluation of Target Engagement by the Cyclin-Dependent Kinase 4 and 6 Inhibitor Palbociclib Correlates with Cancer Cell Response
Nomanbhoy, Tyzoon K, Sharma, Geeta, Brown, Heidi, Wu, Jiangyue, Aban, Arwin, Vogeti, Subha, Alemayehu, Senait, Sykes, Maria, Rosenblum, Jonathan S, Kozarich, John W
Published in Biochemistry (Easton) (27.09.2016)
Published in Biochemistry (Easton) (27.09.2016)
Get full text
Journal Article
Discovery of acyl ureas as highly selective small molecule CSF1R kinase inhibitors
Caldwell, Timothy M., Kaufman, Michael D., Wise, Scott C., Mi Ahn, Yu, Hood, Molly M., Lu, Wei-Ping, Patt, William C., Samarakoon, Thiwanka, Vogeti, Lakshminarayana, Vogeti, Subha, Yates, Karen M., Bulfer, Stacie L., Le Bourdonnec, Bertrand, Smith, Bryan D., Flynn, Daniel L.
Published in Bioorganic & medicinal chemistry letters (15.10.2022)
Published in Bioorganic & medicinal chemistry letters (15.10.2022)
Get full text
Journal Article
Discovery of 1‑(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3‑d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells
Henry, James R, Kaufman, Michael D, Peng, Sheng-Bin, Ahn, Yu Mi, Caldwell, Timothy M, Vogeti, Lakshminarayana, Telikepalli, Hanumaiah, Lu, Wei-Ping, Hood, Molly M, Rutkoski, Thomas J, Smith, Bryan D, Vogeti, Subha, Miller, David, Wise, Scott C, Chun, Lawrence, Zhang, Xiaoyi, Zhang, Youyan, Kays, Lisa, Hipskind, Philip A, Wrobleski, Aaron D, Lobb, Karen L, Clay, Julia M, Cohen, Jeffrey D, Walgren, Jennie L, McCann, Denis, Patel, Phenil, Clawson, David K, Guo, Sherry, Manglicmot, Danalyn, Groshong, Chris, Logan, Cheyenne, Starling, James J, Flynn, Daniel L
Published in Journal of medicinal chemistry (28.05.2015)
Published in Journal of medicinal chemistry (28.05.2015)
Get full text
Journal Article
Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2
Smith, Bryan D, Kaufman, Michael D, Leary, Cynthia B, Turner, Benjamin A, Wise, Scott C, Ahn, Yu Mi, Booth, R John, Caldwell, Timothy M, Ensinger, Carol L, Hood, Molly M, Lu, Wei-Ping, Patt, Tristan W, Patt, William C, Rutkoski, Thomas J, Samarakoon, Thiwanka, Telikepalli, Hanumaiah, Vogeti, Lakshminarayana, Vogeti, Subha, Yates, Karen M, Chun, Lawrence, Stewart, Lance J, Clare, Michael, Flynn, Daniel L
Published in Molecular cancer therapeutics (01.09.2015)
Published in Molecular cancer therapeutics (01.09.2015)
Get full text
Journal Article
Abstract 3092: In-situ Kinome wide profiling of Palbociclib treated COLO-205 human tumor xenograft samples
Sharma, Geeta, Vogeti, Subha, Grant, Wendy, Wu, Shuzhen, Dias, Christa, Nomanbhoy, Tyzoon, Wu, Jiangyue, Aban, Arwin
Published in Cancer research (Chicago, Ill.) (01.08.2015)
Published in Cancer research (Chicago, Ill.) (01.08.2015)
Get full text
Journal Article
Abstract 3925: Inhibition of oncogenic and drug-resistant PDGFRA and KIT alterations by DCC-2618
Smith, Bryan D., Kaufman, Michael D., Gupta, Anu, Leary, Cynthia B., Lu, Wei-ping, Bulfer, Stacie L., Al-Ani, Gada, Singh, Jarnail, Vogeti, Subha, Heinrich, Michael C., Flynn, Daniel L.
Published in Cancer research (Chicago, Ill.) (01.07.2018)
Published in Cancer research (Chicago, Ill.) (01.07.2018)
Get full text
Journal Article
Abstract B129: Preclinical studies with DCC-3116, an ULK kinase inhibitor designed to inhibit autophagy as a potential strategy to address mutant RAS cancers
Smith, Bryan D, Vogeti, Lakshminarayana, Gupta, Anu, Singh, Jarnail, Al-Ani, Gada, Bulfer, Stacie L, Caldwell, Timothy M, Timson, Mary J, Vogeti, Subha, Ahn, Yu Mi, Al-Hashimi, Hikmat, Crawley, Chase K, Heiniger, Cale L, Leary, Cynthia B, Proto, Justin T, Shen, Quanrong, Telikepalli, Hanumaiah, Yates, Karen, Lu, Wei-Ping, Flynn, Daniel L
Published in Molecular cancer therapeutics (01.12.2019)
Published in Molecular cancer therapeutics (01.12.2019)
Get full text
Journal Article
Abstract B23: Chemoproteomic profiling of native kinases during the treatment of cells with kinase inhibitors
Nomanbhoy, Tyzoon K., Brown, Heidi E., Wu, Jiangyue, Vogeti, Subha, Aban, Arwin, Grant, Wendy, Senait, Alemayehu, Wu, Shuzhen, Dias, Christa, Sharma, Geeta
Published in Cancer research (Chicago, Ill.) (01.02.2016)
Published in Cancer research (Chicago, Ill.) (01.02.2016)
Get full text
Journal Article
Abstract A53: The specific FMS kinase inhibitor, DCC-3014, durably inhibits FMS kinase in vivo and blocks cancer bone invasiveness
Smith, Bryan D., Kaufman, Michael D., Leary, Cynthia B., Hood, Molly M., Lu, Wei-Ping, Turner, Benjamin A., Vogeti, Subha, Wise, Scott C., Flynn, Daniel L.
Published in Cancer research (Chicago, Ill.) (01.01.2015)
Published in Cancer research (Chicago, Ill.) (01.01.2015)
Get full text
Journal Article
Abstract 4033: Pan-exon mutant KIT inhibitor DCC-3009 demonstrates tumor regressions in preclinical gastrointestinal stromal tumor models
Smith, Bryan D., Vogeti, Subha, Caldwell, Timothy M., Telikepalli, Hanumaiah, Ahn, Yu Mi, Al-Ani, Gada, Bulfer, Stacie L., Greenwood, Andrew, Heiniger, Cale L., Large, Joshua W., Leary, Cynthia B., Lu, Wei-Ping, Luther, Kylie, Patt, William C., Petty, Max D., Romero, Yeni K., Stanley, Forrest A., Stoltz, Kristen L., Tanner, Daniel C., Yang, Sihyung, Zhan, Yu, Bourdonnec, Bertrand Le, Flynn, Daniel L.
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Get full text
Journal Article
Abstract 4045: DCC-3084, a RAF dimer inhibitor, broadly inhibits BRAF class I, II, III, BRAF fusions, and RAS-driven solid tumors leading to tumor regression in preclinical models
Bulfer, Stacie L., Bourdonnec, Bertrand Le, Zwicker, Jeffery D., Ahn, Yu Mi, Al-Ani, Gada, Al-Hashimi, Hikmat, Crawley, Chase, Elliott, Kristin M., Faisal, Saqib, Harned, Andrew M., Heiniger, Cale L., Hood, Molly M., Javed, Salim, Kennedy, Michael, Large, Joshua W., Leary, Cynthia B., Lu, Wei-Ping, Luther, Kylie, Petty, Max D., Picard, Hunter R., Proto, Justin T., Romero, Yeni K., Stanley, Forrest A., Stoltz, Kristen L., Tanner, Daniel C., Telikepalli, Hanumaiah, Timson, Mary J., Vogeti, Lakshminarayana, Vogeti, Subha, Yang, Sihyung, Zhong, Lexy H., Smith, Bryan D., Flynn, Daniel L.
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Get full text
Journal Article
Abstract DDT02-02: Identification of LY3009120 as a pan inhibitor of Raf isoforms and dimers with minimal paradoxical activation and activities against BRaf or Ras mutant tumor cells
Peng, Sheng-Bin, Henry, James, Kaufman, Michael, Lu, Wei-Ping, Smith, Bryan D., Vogeti, Subha, Wise, Scott, Zhang, Youyan, Horn, Robert Van, Zhang, Xiaoyi, Yin, Tinggui, Yadav, Vipin, Huber, Lysiane, Kays, Lisa, Walgren, Jennie, McCann, Denis, Patel, Phenil, Buchanan, Sean, Conti, Ilaria, Starling, James J., Flynn, Daniel L.
Published in Cancer research (Chicago, Ill.) (01.10.2014)
Published in Cancer research (Chicago, Ill.) (01.10.2014)
Get full text
Journal Article